Debiopharm Group to Support Ascepion in the Development of Debio 1144 for the Treatment of Chinese Cancer Patients
LAUSANNE, Switzerland and SUZHOU, China, April 18, 2013 /PRNewswire/ –
Suzhou Ascepion Pharmaceuticals, Inc. (Ascepion), a Chinese leading biotech company
focusing on the discovery and development of world-class molecular targeted innovative
drugs and Debiopharm Group(TM) (Debiopharm), a Swiss-based global biopharmaceutical group
of companies, announced today that Debiopharm will support further development in China of
Debio 1144, a small molecule in preclinical development for the treatment of a large
spectrum of solid tumors.
Debiopharm and Ascepion had previously signed a license agreement for the development
and commercialization of Debio 1144, an orally available multikinase inhibitor. After
having generated positive preclinical results with the product, Debiopharm has decided to
support Ascepion for further development of Debio 1144 in China as it is well designed for
the treatment of certain types of cancers that are highly represented in China.
“This is an opportunity for Ascepion to develop an anti-cancer agent tailored to the
Chinese market,” said Rolland-Yves Mauvernay, President and founder of Debiopharm
Group(TM). “At Debiopharm we value sharing our competences with a Chinese company in view
of developing a product with a potential to treat various cancers highly prevalent in
“The disease spectrum of the Chinese population suggests the product will be well
suited for its market. Thus it holds a great promise for certain cancer types in Chinese
patients,” commented Dr. Shan Jiang, President and CEO of Ascepion Pharmaceuticals.
About Debio 1144
Debio 1144 is a multikinase inhibitor, which has demonstrated strong efficacy in
several preclinical models. It is orally available and has a large therapeutic index.
About Suzhou Ascepion Pharmaceuticals Inc.
Based in Suzhou, China, Suzhou Ascepion Pharmaceuticals, Inc. is a leading
biopharmaceutical company in China dedicated to the discovery and development of
breakthrough small molecule drugs. Suzhou Ascepion Pharmaceuticals possesses a fully
integrated platform and proprietary technologies for the discovery and development of
small molecule therapeutics targeting signal transduction pathways in a systematic and
productive manner. The company has developed a pipeline of innovative small molecule drugs
for the treatment of oncology and related diseases. For additional information on Suzhou
Ascepion Pharmaceuticals, please visit http://www.ascepion.com.
About Debiopharm Group(TM)
Debiopharm Group(TM) (Debiopharm) is a Swiss-based global biopharmaceutical group of
companies with a focus on the development of prescription drugs that target unmet medical
needs. The group in-licenses, develops and/or co-develops promising biological and small
molecule drug candidates having reached clinical development phases I, II or III, as well
as earlier stage candidates. It develops its products for global registration and maximum
commercial potential. The products are out-licensed to pharmaceutical partners for sales
and marketing. Debiopharm is also active in the field of companion diagnostics with a view
to progressing in the area of personalized medicine. Debiopharm independently funds the
worldwide development of all of its products while providing expertise in pre-clinical and
clinical trials, manufacturing, drug delivery and formulation, and regulatory affairs.
For more information about Debiopharm Group(TM), please visit:
Debiopharm S.A. Contact Mrs Beatrice Hirt Communication Coordinator Tel.: +41(0)21-321-01-11 Fax: +41(0)21-321-01-69 firstname.lastname@example.org Additional Media Contacts In London Maitland Brian Hudspith Tel: +44(0)20-7379-5151 email@example.com In New York Russo Partners, LLC Martina Schwarzkopf, Ph.D. Account Executive Tel: +1-212-845-4292 Fax: +1-212-845-4260 firstname.lastname@example.org Ascepion Contact Ms. Min Wang Corporate administration Tel.: +86-512-62956001 Fax: +86-512-62956001-8004 email@example.com
SOURCE The Debiopharm Group